CytoMed Therapeutics GDTC
NASDAQ GDTC
$0.84 +0.00 (+0.49%)
At close: Nov 11, 2026 · 4:00 PM EST

CytoMed Therapeutics (GDTC) Debt Ratio (2021 - 2026)

Updated

CytoMed Therapeutics' Debt Ratio came in at 0.11 for Q2 2026, compared with 0.00 a year earlier.

Analysis

CytoMed Therapeutics (GDTC) Debt Ratio (2021 - 2026) Analysis & Trends

For FY2025, CytoMed Therapeutics' Debt Ratio was 0.05, up 492.8% from FY2024.

  • Going back by year, Debt Ratio was 0.01 in FY2024 (+33.6%), 0.01 in FY2023 (-99.3%), 0.99 in FY2022 (+50.9%) and 0.66 in FY2021.
  • The Q2 2026 figure represents the highest quarterly Debt Ratio since Q4 2022.
Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Debt Ratio (Qtr)
1 Eli Lilly 1,348.13 Bn 1,321.74 Bn 20.46 Bn 0.33
2 Johnson & Johnson 675.90 Bn 595.76 Bn 17.30 Bn 0.23
3 AbbVie 519.45 Bn 487.50 Bn 13.12 Bn 0.55
4 Merck 364.95 Bn 327.95 Bn 13.19 Bn 0.41
5 Novartis Ag 311.58 Bn 285.16 Bn - -
6 Astrazeneca 289.34 Bn 262.94 Bn 13.26 Bn -0.06
7 Amgen 251.64 Bn 203.30 Bn 7.58 Bn 0.56
8 Gilead Sciences 212.05 Bn 187.07 Bn 6.73 Bn 0.51
9 Pfizer 167.35 Bn 115.00 Bn 12.56 Bn 0.31
10 CytoMed Therapeutics 9.94 Mn -2.19 Mn - 0.01
Historic Data

Historic Data

Download Data
DateValue
Jun 30, 2026 0.01
Dec 31, 2025 0.05
Jun 30, 2025 0.05
Dec 31, 2024 0.04
Jun 30, 2024 0.04
Dec 31, 2023 0.04
Jun 30, 2023 0.03
Dec 31, 2022 0.80
Dec 31, 2021 0.53
API Access

CytoMed Therapeutics Debt Ratio API

Pull this series into your own models, spreadsheets and apps with the Business Quant Historical Metrics API. The request below matches the chart above — change the frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/historic?slug=debt-ratio&ticker=GDTC&period=max&api_key=YOUR_API_KEY